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Abstract: Osteoporosis is common in patients with chronic obstructive pulmonary disease 
(COPD). Data regarding the relationship between adipokines and bone mineral density (BMD) 
in this population is lacking. The purpose of this pilot study was to determine associations 
between the adipokines tumor necrosis factor-alpha (TNF-α), leptin, adiponectin and resistin, 
body composition, and BMD in men with severe COPD. This was a cross-sectional study of 
men with severe COPD who visited the University of Colorado Hospital COPD Center. Bone 
density and parameters of body composition were measured by dual-energy X-ray absorpti-
ometry. Twenty-three men were included (mean age = 66 years, mean percent predicted forced 
expiratory volume in one second = 32%). On bivariate analysis, there was no association 
between TNF-α and BMD. Parameters of body composition and serum concentrations of leptin 
and adiponectin were significantly associated with total hip and spine bone density. However, 
with partial correlation analysis, total body mass was the only independent predictor of total 
hip BMD, explaining approximately 50% of the variability. Overall, 18 out of 23 men enrolled 
(78%) had low bone density by T-score, and nine (39%) were classified as having osteoporosis. 
The men with osteoporosis had lower parameters of body composition, lower mean serum leptin 
concentrations, and a greater impairment in measures of lung function compared to the men 
without osteoporosis. We conclude that the effect of adipokines on BMD does not appear to be 
independent of body mass. However, larger studies are needed to further evaluate the relation-
ship between adipokines, body weight, and BMD in patients with COPD.
Keywords: bone mineral density, osteoporosis, TNF-α, leptin, adiponectin, chronic obstructive 
pulmonary disease, adipokines
Introduction
Patients with chronic obstructive pulmonary disease (COPD) are at high risk for 
developing osteoporosis with a reported incidence ranging from 36%–60%.1–4 
Osteoporosis-related fractures of the hip and spine increase pain and disability, reduce 
quality of life, and can increase the risk for death by 2–3-fold.5,6 In addition to factors 
that increase the risk for osteoporosis in the general population (eg, family history), 
there are several factors specific to patients with COPD that increase their risk for bone 
loss and fractures. A long history of cigarette smoking is the primary cause for the 
development of COPD in up to 80%–90% of patients and smoking is considered an 
independent risk factor for the development of osteoporosis.7–11 Patients with COPD 
are frequently treated with systemic corticosteroids, which have been associated with 
significant and rapid increases in bone loss and fracture risk when used chronically.12–14 
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explained by corticosteroid use as several cross-sectional 
studies have demonstrated low bone mineral density (BMD) 
and high fracture rates in patients with COPD not receiving 
systemic corticosteroids.1,3,15–18 Impaired lung function 
(as measured by forced expiratory volume in one second 
[FEV1]) has been shown to be an independent predictor of 
osteoporosis in several cross-sectional studies of patients 
with and without COPD.19–25 The extent of pulmonary 
emphysema has also been demonstrated to have a significant 
negative correlation with BMD.26 As the severity of COPD 
worsens, dyspnea can limit a patient’s mobility. This may 
lead to significant disability, deconditioning, and lack of 
physical activity, which has been associated with bone loss 
and increased fracture risk.27
Low body weight and weight loss are well documented 
predictors of bone loss and independent predictors of 
increased fracture risk.28–31 Approximately 35%–60% of 
patients with moderate to severe COPD have a low body 
mass index (BMI) or evidence of weight loss.32 In several 
cross-sectional studies, a low BMI was the only factor inde-
pendently correlated with osteoporosis risk in patients with 
COPD.3,15,17,33–36 Therefore, body weight appears to play an 
important role in osteoporosis risk in patients with COPD.
Patients with COPD have an increased risk for osteoporosis. 
While many underlying factors contribute to this process, 
they do not completely explain the increased risk. One area 
that deserves further investigation is the role of adipokines 
in the development osteoporosis in this population. Adipose 
tissue produces and releases substances called adipokines 
which include tumor necrosis factor-alpha (TNF-α), leptin, 
adiponectin, and resistin.37 It has been hypothesized that the 
effect of body weight on BMD might be mediated through 
the effects of these adipokines on bone remodeling.38 
Several studies have demonstrated associations between 
adipokines and BMD in various patient populations with 
conflicting results.39–50 Studies of adipokines in patients 
with COPD are limited and to our knowledge, no published 
studies have evaluated the relationship between TNF-α, 
leptin, adiponectin or resistin and BMD in patients with 
COPD. Therefore, the purpose of this pilot study was 
to evaluate the relationship between adipokines, body 
composition and BMD in men with severe, stable COPD.
Materials and methods
study objectives
The primary objective of this study was to evaluate the 
relationship between TNF-α and its receptors tumor necrosis 
factor receptor (TNFR)-1 and TNFR-2 and total hip and 
lumbar spine BMD in men with severe COPD. The secondary 
objectives were (1) to evaluate the relationship between 
leptin, adiponectin, and resistin and total hip and lumbar 
spine BMD, (2) to evaluate the relationship between TNF-α, 
TNFR-1, TNFR-2, leptin, adiponectin and resistin and body 
composition, and (3) to compare clinical characteristics, 
parameters of body composition, pulmonary function, and 
adipokine levels in men with severe COPD who have osteo-
porosis and osteopenia or normal bone density.
Patients
This was a cross-sectional pilot study. Patients meeting 
inclusion criteria were recruited from the University of 
Colorado Hospital COPD Center. The study was approved 
by the Colorado Multiple Institutional Review Board and 
informed consent was obtained from all participants.
Patients were included in the study if they were male, 
between the age of  45 to 89 years, had severe COPD defined 
as the ratio of FEV1 to forced vital capacity (FVC) 0.70 
and FEV1 postbronchodilator 50% predicted and their 
COPD had been clinically stable for the last two months. 
Clinically stable COPD was defined as no record of 
pulmonary infections, COPD exacerbations, or change in 
COPD-related medications within the last two months. 
Patients were excluded if they had a history of asthma or 
significant bronchodilator reversibility; diagnosis of systolic 
heart failure (left ventricular ejection fraction 45%); 
chronic kidney disease (defined as an estimated glomerular 
filtration rate  60 ml/min for 3 months); current infection; 
human immunodeficiency virus; pulmonary infection within 
the last two months; significant liver impairment (defined by 
elevations in aminotransferases of  2 × upper limit of normal); 
a history of collagen vascular, rheumatologic, neoplastic or 
thyroid disorders; untreated hypogonadism, or any underly-
ing cause for metabolic bone disease; treatment with drugs 
known to alter bone metabolism including: bisphosphonates, 
teriparatide, or calcitonin; treatment with drugs known to 
alter TNF-α concentrations (eg, pentoxifylline, melatonin); 
and a history of continuous oral corticosteroid use (defined 
as continuous administration for three or more weeks) within 
the previous two years. A history of inhaled corticosteroid 
use or short bursts of oral corticosteroids for 3 weeks were 
permitted.
study visits
Patients were required to attend two study visits. The first 
visit took place at the University of Colorado Hospital COPD 
Center where subjects underwent a brief interview, a urine International Journal of COPD 2009:4 269
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sample was collected, and venous blood samples were drawn. 
The second visit took place at the University Of Colorado 
Clinical Nutrition Research Unit Energy Balance Lab where 
body composition and bone density were obtained using 
dual-energy X-ray absorptiometry (DXA).
Data collection
The following information was collected from the patient’s 
medical record: age, race/ethnicity, average number of 
COPD exacerbations per year (based on data within the last 
two years), smoking history (current or past and pack-years), 
past medical history, current medications, oxygen use, most 
recent six-minute walk test data and full pulmonary function 
test results conducted during stable disease (FEV1, FVC, 
FEV1/FVC ratio, diffusion capacity of carbon monoxide 
[DLCO], residual volume [RV], total lung capacity [TLC], 
thoracic gas volume [TGV]).
All patients were interviewed by a study investigator at 
the first study visit regarding risk factors for osteoporosis 
including: family history of osteoporosis, calcium and 
vitamin D intake (daily supplements and dietary intake), 
and personal history of fracture. Data collected from the 
medical record was clarified with the patient during the 
interview (eg, past medical history, smoking history, current 
medications).
Collection and analysis of blood samples
Venous blood samples were collected into three serum 
separator tubes by the University of Colorado Hospital 
clinical laboratory phlebotomist. Due to the timing of the 
COPD clinic visits, patients were not required to fast prior 
to the blood draw. Two serum separator tubes were sent to 
the University of Colorado Hospital clinical laboratory for 
immediate analysis of total testosterone, estradiol, osteocal-
cin (biomarker for bone formation), and 25-hydroxyvitamin 
D (25-OHD). Total testosterone was measured by chemilumi-
nescence using the Beckman-Coulter Access Immunoassay 
System (Fullerton, CA), reference range 200–850 ng/dL; 
25-OHD was measured by chemiluminescence using Nichols 
Institute Diagnostic (San Juan Capistrano, CA), reference 
range 9–57 ng/mL; estradiol was measured by chemilu-
minescence using the Beckman-Coulter Access Immu-
noassay System (Fullerton, CA), male reference range 
20–75 pg/mL, and osteocalcin was measured by DiaSorin 
competitive radioimmunoassay (Stillwater, MN), reference 
range 1.1–10.8 ng/mL.
The other serum separator tubes were used for batch 
analysis of TNF-α, TNFR-1, TNFR-2, leptin, adiponectin, 
and resistin. Within one hour of collection, the serum 
was separated from blood cells by centrifugation at 
1,000 × g for 15 minutes. It was harvested with sterile transfer 
pipettes, aliquotted into 0.5 ml serum tubes and immediately 
stored at -80 °C. Serum TNF-α, TNFR-1, TNFR-2, leptin, 
adiponectin, and resistin concentrations were measured in 
duplicate with enzyme-linked immunosorbent (ELISA) 
kits (Quantikine HS and Quantikine; R&D Systems, Inc., 
Minneapolis, MN). The intra-assay and inter-assay coefficient 
of variations for these tests are as follows TNF-α = 5.3%–8.8% 
and 10.8%–16.7%, TNFR-1 = 3.6%–5.0% and 3.7%–8.8%, 
TNFR-2 = 2.6%–4.8% and 3.5%–5.1%, leptin = 3.0%–3.3% 
and 3.5%–5.4%, adiponectin = 2.5%–4.7% and 5.8%–6.8%, 
and resistin = 3.8%–5.3% and 7.8%–9.2%, respectively.
Measurement of urinary nTX
Urinary N-telopeptide (NTX), an important biomarker for 
bone turnover, was obtained in all patients. On enrollment, 
all subjects were given a sterile specimen cup and instructed 
to collect a single second-morning void urine sample the day 
of the first study visit. Subjects were instructed to keep the 
urine sample refrigerated until the time of the study visit. This 
urine sample was sent to the University of Colorado Hospital 
clinical laboratory for determination of NTX, which was 
measured by ELISA (Ostex International Inc., Seattle, WA) 
and expressed as a ratio to urinary creatinine concentrations. 
Normal adult male reference range = 20–83 nmol BCE/mmol 
creatinine.
Measurement of BMD 
and body composition
Whole body composition, and BMD of the lumbar spine 
(L1–4), total hip, femoral neck and total body were measured 
by DXA using the Hologic Delphi W densitometer (Hologic 
Corp, Waltham, MA). Subjects were scanned in light clothing 
while lying in the supine position. The precision of BMD 
measurements using this instrument was 1.5% and the 
standard deviations for repeated measurements of fat free 
mass and fat mass was 0.5 kg. Prior to the scan, height was 
measured to the nearest 0.5 centimeters using a wall-mounted 
stadiometer with the patient in their bare feet, and weight 
was measured to the nearest 0.1 kg with subjects barefoot 
and in light clothing. The weight in kg divided by height in 
meters2 was used to calculate BMI.
statistical analysis
Data are presented as means ± standard deviations. P values 
less than 0.05 are considered statistically significant. International Journal of COPD 2009:4 270
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Adiponectin, leptin, resistin, and total body mass were 
log-transformed to normalize distribution. Pearson’s 
Correlation Test was performed to evaluate for potential 
relationships. For the secondary analyses, covariates were 
chosen based on a significant relationship with total hip 
BMD (P  0.05). Collinear variables were eliminated 
using a cluster analysis. Partial correlation analysis was 
performed on the selected covariates with total hip BMD 
as the dependent variable and adjusting for total body 
mass. Patients were divided into groups according to the 
presence or absence of osteoporosis based on T-score and 
history of low trauma fracture. Continuous variables were 
compared between patient groups using the Wilcoxon test. 
Nominal data were compared using Chi-square or Fischer’s 
exact test. Pearson’s correlation test was performed using 
GraphPad Prism 4 software (San Diego, CA). All other 
statistical analyses were performed using R Statistical 
Package, Version 2.4.1 (http://www.r-project.org).
Results
Twenty-five patients were enrolled in the study. Two patients 
were excluded. One patient died prior to completing the study 
and one patient was excluded after completing the study due 
to a reported history of childhood asthma, and pulmonary 
function testing that revealed significant reversibility and a 
normal diffusion capacity. Twenty-three patients are included 
in this analysis.
The general characteristics of the entire study population 
are presented in Table 1. All patients were Caucasian. The 
mean age was 66 (8.7) years and the mean FEV1 was 32% 
(11) of predicted. Approximately 80% of patients were on 
inhaled corticosteroids and chronic oxygen therapy. Based 
on DXA T-scores, 30% of patients had bone densities 
in the osteoporotic range and an additional 48% in the 
osteopenic range.
On bivariate analysis, there was no relationship between 
TNF-α, TNFR-1, or TNFR-2 and total hip BMD or lumbar 
spine BMD (Table 2). There was also no significant correla-
tion between TNF-α, TNFR-1, or TNFR-2 and parameters of 
body composition (data not shown). There was a significant 
positive correlation with serum leptin concentrations, and 
a significant negative correlation with serum adiponectin 
concentrations and total hip and spine BMD (Table 2). 
However, after adjusting for total body mass, which had 
the strongest association (r2 = 0.48); correlations been total 
hip and spine BMD and serum concentrations of leptin and 
adiponectin were no longer significant. There were no sig-
nificant correlations between total hip and spine BMD and 
serum concentrations of testosterone, estradiol, osteocalcin, 
and 25-OHD or urinary NTX.
Selected bivariate correlations with serum leptin and 
adiponectin are summarized in Table 3. Serum leptin 
concentrations were significantly positively correlated with 
parameters of body composition and negatively correlated 
with urinary NTX, and lung volumes (Table 3). In contrast, 
serum adiponectin concentrations had a smaller, yet signifi-
cant, negative correlation with parameters of body compo-
sition and demonstrated a significant negative correlation 
with serum concentrations of resistin, TNFR-1 and TNFR-2. 
There was a significant inverse relationship between leptin 
and adiponectin.
Characteristics of the study population stratified according 
to osteoporosis status are summarized in Table 4. All body 
composition parameters were significantly lower in the patients 
with osteoporosis (Table 5). There was no significant differ-
ence between the groups with regards to total testosterone, 
estradiol, 25-OHD concentrations, and markers of bone 
turnover. Patients with osteoporosis had significantly lower 
mean % predicted FEV1 (24.5 vs 37; P = 0.003) and DLCO 
(29.4 vs 42.1; P = 0.036) values and there was a trend towards 
higher lung volumes. Serum leptin was significant lower 
(3.8 vs 9.8 ng/mL; P = 0.046) and adiponectin concentrations 
Table 1 general characteristics of the study population
Characteristic (n = 23)
Age (years) 66 (8.7)
Caucasian, n (%) 23 (100)
Body mass index (kg/m2) 26.4 (6.9)
FeV1 (% of predicted) 32 (11)
history of smoking, n (%) 23 (100)
  Current, n (%) 5 (22)
  Pack-years 60.8 (22.3)
home oxygen, n (%) 19 (83)
Pulmonary medications, n (%)
  Inhaled corticosteroid 19 (79)
  Long-acting inhaled B2-agonist 13 (57)
  Long-acting inhaled anticholinergic 11 (43)
Total hip BMD T-score -1.1 ± 1.1
Lumbar spine BMD T-score -1.2 ± 1.2
normal, n (%)a 5 (22)
Osteopenia, n (%)a 11 (48)
Osteoporosis, n (%)a   7 (30)
Notes: Values given as mean (SD) unless otherwise specified.  aWorld health 
Organization Criteria using dual-energy x-ray absorptiometry BMD T-scores.
Abbreviations: FeV1, forced expiratory volume in one second; BMD, bone mineral 
density.International Journal of COPD 2009:4 271
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trended higher (8969.2 vs 3333.2 ng/mL; P = 0.07) in the 
osteoporosis group.
Discussion
Osteoporosis is common in men with severe COPD. In our 
study, 78% of the men enrolled had low bone density 
and nearly 40% were classified as having osteoporosis. 
Those patients with osteoporosis had worse lung disease 
as evidenced by lower mean % predicted FEV1 and DLCO 
values compared to those without osteoporosis. In addition, 
all body composition parameters were significantly lower in 
this population, as were mean serum leptin concentrations. 
There was no difference in serum concentrations of TNF-α or 
its receptors. On bivariate analysis of the total study population, 
there was no association between TNF-α and BMD. 
Parameters of body composition, lung volumes, and serum 
leptin and adiponectin concentrations were significantly 
associated with total hip and spine BMD. However, consistent 
with previous studies, body mass was the only independent 
predictor of BMD at these sites.3,33,51 Approximately 50% of 
the variability in total hip BMD could be accounted for by 
the total body mass in this population.
The relationship between body weight and BMD is 
complex and not completely understood. Possible expla-
nations for the protective bone effects of increased body 
weight include increased aromatization of androgens to 
estrogen in adipose tissue, mechanical loading, lower levels 
of sex hormone-binding globulin, and increased bone forma-
tion due to high circulating insulin levels.52 Adipose tissue 
produces and releases a variety of proinflammatory and anti-
inflammatory factors including TNF-α, leptin, adiponectin, 
and resistin.37,53 It has been hypothesized that the effect of 
Table 2 selected bivariate correlations with total hip and spine bone mineral density
Parameter Total hip BMD   Spine BMD
R p R p
Adipokines
  TnF-α (ng/mL) 0.014 0.95 -0.016 0.94
  TnFR-1 (pg/mL) 0.216 0.32 -0.028 0.90
  TnFR-2 (ng/mL) 0.233 0.28 0.073 0.74
  Leptin (ng/mL) 0.616 0.002a 0.456 0.03
  Adiponectin (ng/mL) -0.531 0.009a -0.426 0.04
  Resistin (ng/mL) 0.225 0.30 -0.194 0.38
Body composition
  Body mass index (kg/m2) 0.600 0.003 0.483 0.02
  Total fat (kg) 0.635 0.001 0.443 0.03
  Total lean (kg) 0.633 0.001 0.579 0.004
  Total body mass (kg) 0.690 0.0003a 0.564 0.005
Markers of bone turnover
  Osteocalcin (ng/mL) -0.161 0.46 -0.40 0.06
    Urinary nTX (nmol BCe/mmol creatinine) -0.302 0.16 -0.328 0.13
hormones
  Testosterone (ng/dL) -0.265 0.57 -0.104 0.64
  estradiol (pg/mL) 0.184 0.40 0.293 0.17
  25-OhD (ng/mL) -0.232 0.29 -0.079 0.72
Lung function
  FeV1 % P 0.405 0.06 0.329 0.13
  DCLO % P 0.354 0.11 0.111 0.62
  TgV % P -0.541 0.009 -0.342 0.12
  TLC % P -0.555 0.007a -0.360 0.10
  RV % P -0.490 0.02 -0.359 0.10
Notes: ano correlations were seen between total hip BMD and TLC % P, leptin, and adiponectin after adjustment for total body mass with partial correlation analysis.
Abbreviations: BMD, bone mineral density; TnF, tumor necrosis factor; TnFR, tumor necrosis factor receptor; nTX, n-telopeptide; 25-OhD, 25-hydroxy vitamin D; FeV1 % 
P, forced expiratory volume in one second percent predicted; DLCO % P, diffusion capacity of carbon monoxide percent predicted; TgV % P, thoracic gas volume percent 
predicted; TLC % P, total lung capacity percent predicted; RV % P, residual volume percent predicted.International Journal of COPD 2009:4 272
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body weight on BMD might be mediated through the effects 
of these adipokines on bone remodeling.
Tumor necrosis factor-α has been implicated as contrib-
uting to cachexia in various chronic disease populations and 
elevated levels of TNF-α have been demonstrated in patients 
with COPD who have a low body weight or reduced skeletal 
muscle.35,36,54–59 TNF-α is a potent stimulator of osteoclastic 
bone resorption and has been linked to bone loss in several 
inflammatory disease states such as rheumatoid arthritis, 
inflammatory bowel disease, and ankylosing spondylitis.32,60–63 
It was postulated that elevated levels of TNF-α may contribute 
to the low body weight and low BMD in patients with COPD. 
However, in our study, there was no difference in serum 
concentrations of TNF-α, or its receptors TNFR-1 and TNFR-2 
between patients with or without osteoporosis and they did not 
significantly correlate with BMD or bone turnover markers. 
Our results do not rule out the potential that the TNF system 
plays a role in cachexia and bone loss in patients with COPD. 
Evaluation of TNF-α at one time point may not be able to 
capture the long-term systemic inflammation picture. It is 
possible that increases in TNF-α during acute exacerbations 
contribute to bone loss and that levels are not significantly 
elevated during stable phases of the disease.64 Nearly 80% of 
our patients were on high-dose inhaled corticosteroids. It is 
unknown whether inhaled steroid use could have impacted 
the TNF results. Studies that demonstrate elevated levels of 
TNF-α in patients with COPD do not report the incidence of 
inhaled corticosteroid use by the study population.
The role of leptin in bone turnover and osteoporosis is not 
completely understood. In vitro data suggest that leptin stimu-
lates bone formation possibly by acting on human marrow 
stromal cells to enhance osteoblast and inhibit adipocyte 
Table 3 selected bivariate correlations with serum leptin and adiponectin
Parameter Leptin Adiponectin
R p R p
Adipokines
  Leptin (ng/mL) – – -0.648 0.0008
  Adiponectin (ng/mL) -0.648 0.0008 – –
  Resistin (ng/mL) 0.268 0.22 -0.417 0.048
  TnF-α (ng/mL) 0.038 0.86 -0.243 0.26
  TnFR-1(pg/mL) 0.266 0.22 -0.552 0.006
  TnFR-2 (ng/mL) 0.298 0.17 -0.557 0.006
Body composition
  Body mass index (kg/m2) 0.800 0.0001 -0.658 0.0006
  Total fat (kg) 0.836 0.0001 -0.629 0.001
  Total lean (kg) 0.442 0.04 -0.319 0.14
  Total body mass (kg) 0.7586 0.0001 -0.601 0.002
Bone mineral density
  Total body BMD (g/cm2) 0.550 0.007 -0.462 0.03
  Total hip BMD (g/cm2) 0.616 0.002 -0.531 0.009
    Lumbar spine BMD (gm/cm2) 0.456 0.03 -0.426 0.04
Markers of bone turnover
  Urinary nTX (nmol BCe/mmol creatinine) -0.702 0.0002 0.463 0.03
  Osteocalcin (ng/mL) 0.048 0.83 -0.004 0.99
Lung function
  FeV1 % P 0.328 0.13 -0.387 0.07
  DCLO % P 0.264 0.23 -0.266 0.23
  TgV % P -0.620 0.002 0.457 0.03
  TLC % P -0.561 0.007 0.444 0.04
  RV % P -0.552 0.008 0.357 0.10
Abbreviations: BMD, bone mineral density;   TnF, tumor necrosis factor;   TnFR, tumor necrosis factor receptor; nTX, n-telopeptide; FeV1 % P, forced expiratory volume 
in one second percent predicted; DLCO % P, diffusion capacity of carbon monoxide percent predicted;   TgV % P, thoracic gas volume percent predicted;   TLC % P, total lung 
capacity percent predicted; RV % P, residual volume percent predicted.International Journal of COPD 2009:4 273
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differentiation.65,66 Leptin also inhibits osteoclastagenesis 
by decreasing the receptor activator of nuclear factor-κB 
(RANK) and its ligand (RANKL) and increasing the 
production of osteoprotegerin (OPG).66 Therefore, reduced 
levels of leptin may result in both reduced bone formation 
and increased bone resorption. The effect of leptin on BMD 
may differ depending on the skeletal site. In a study of 
leptin-deficient mice, cortical thinning was observed, while 
trabecular volume was increased compared to control mice.67 
In addition, adipocyte infiltration was seen in the femoral 
marrow, but not the vertebral marrow of the leptin-deficient 
mice. Therefore, leptin deficiency may have a greater effect 
on hip BMD compared to spine BMD. In our study, there 
was a stronger correlation between leptin and BMD at the 
total hip compared to the lumbar spine.
Leptin concentrations strongly correlate with BMI and 
body fat in patients with COPD.64,68–70 Similar to the literature, 
a strong positive correlation between leptin and parameters 
of body composition was observed in our patients. Data 
regarding the relationship between serum or plasma leptin 
concentrations and bone turnover markers or BMD are 
conflicting.39,40,42–48 In a prospective study of 139 postmeno-
pausal women, plasma leptin was positively correlated with 
BMD at the lumbar spine (r = 0.233; P  0.01), femoral neck 
(r = 0.293; P  0.001) and total body (r = 0.177; P  0.05).39 
These associations remained significant after controlling for 
percent body fat, age, years since menopause and height. 
In a population-based longitudinal study of 302 elderly 
women and men, baseline plasma leptin concentrations 
were significantly associated with BMD at the lumbar spine 
(r = 0.36 and 0.27; P  0.001) and femoral neck (r = 0.35 
and 0.30; P  0.001), but not after controlling for BMI.43 
In a longitudinal cohort study, serum leptin was associated 
with BMD at all sites in both older men and older women 
(P  0.01).45 However, after controlling for covariates such 
as age and BMI, the relationship was only significant in 
women. Similarly, in another cohort study, leptin signifi-
cantly correlated with BMD after adjusting for lean mass 
and age at all sites, but only in the postmenopausal woman 
cohort (r = 0.18–0.42; P  0.05).47 There was no association 
between leptin and BMD in the male cohort. Only one study 
in men has demonstrated an association between leptin and 
BMD after controlling for body weight, but not after control-
ling for other bone-related factors.71
None of these studies evaluated patients with COPD. In 
our study of men with COPD, leptin was positively asso-
ciated with BMD and negatively associated with urinary 
NTX indicating lower BMD and higher bone turnover with 
lower leptin levels. Similar to other studies, this relationship 
between leptin and BMD was not independent of body weight 
in our population. It has been suggested that the relationship 
between leptin and BMD is possibly mediated through the 
association of both variables with body mass and not the 
direct effect of leptin on bone cell numbers or function.43
Weight loss is a potent inducer of adiponectin synthesis.53 
In one study, elevated plasma adiponectin correlated with 
Table 4 Characteristics of patients with and without osteoporosis




Age (years) 65.2 (10.8) 66.4 (6.5)
Body mass index (kg/m2) 22.6 (4.2) 28.9 (7.2)c
history of smoking, n (%) 9 (100) 14 (100)
Current, n (%) 2 (22) 3 (21)
Pack-years 55 (27.7) 64.3 (18.4)
AeCOPD (number/year) 1.3 (2.0) 0.6 (0.9)
home oxygen, n (%) 8 (89) 11 (79)
Pulmonary medications, n (%)
  Inhaled corticosteroid 6 (67) 12 (86)
  Long-acting inhaled B2-agonist 5 (56) 8 (57)
  Long-acting inhaled anticholinergic 4 (44) 6 (43)
Central DXA BMD T-scores
Total hip -1.97 (0.56) -0.49 (0.97)
Lumbar spine -2.24 (1.04) -0.54 (0.73)
Notes:   Values given as mean (SD) unless otherwise specified. aBased on dual-energy X-ray absorptiometry T-score or a history of osteoporotic fracture; bBased on dual-energy 
X-ray absorptiometry T-score; cP = 0.014.
Abbreviations:   AeCOPD, acute exacerbation chronic obstructive pulmonary disease; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry.International Journal of COPD 2009:4 274
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BMI, hyperinflation, and increased TNF-α levels in men 
with COPD.57 Bone mineral density was not evaluated in this 
study. Elevated levels of adiponectin may have a deleterious 
effect on bone through increasing RANKL and inhibiting 
the production of OPG, which would enhance bone resorp-
tion.72 Several studies have demonstrated a significant inverse 
relationship between adiponectin and BMD independent of 
body weight.49,50,73 In a large population-based cohort study, 
a doubling of serum adiponectin in postmenopausal women 
was associated with a mean percent decrease in BMD of 1.8% 
at all sites after controlling for covariate including BMI and 
central fat mass.49 In a cohort study of older men and women, 
adiponectin levels were negatively associated with BMD at 
all sites even after controlling for sex, age, height, fat mass, 
and leptin.74 Despite the correlation between adiponectin and 
BMD, there was no association between adiponectin and 
fracture risk in a subgroup analysis of one of the male cohorts. 
In our study, there was a trend towards higher adiponectin 
levels in patients with osteoporosis and there was a significant 
negative relationship between adiponectin and BMD and a 
significant positive relationship between adiponectin and 
urinary NTX. However, similar to leptin, this relationship 
was not independent of body mass.
Resistin is a pro-inflammatory adipokine, which stimu-
lates synthesis of TNF and other cytokines through a nuclear 
factor-κB-dependent pathway.53 While its role in bone 
metabolism in unknown, one study demonstrated a signifi-
cant inverse correlation between serum resistin and lumbar 
spine BMD after adjustment for age and BMI in men.42 There 
was no correlation between resistin and BMD in our study 
and there was no difference in resistin levels between the 
subjects with or without osteoporosis. Interestingly, resistin 
did significantly correlate with TNFR-1 (r2 = 0.803) and 
TNFR-2 (r2 = 0.514).
Table 5 Comparison of patients with and without osteoporosis






  Leptin (ng/ml) 3.8 (4.7) 9.8 (8.7) 0.046
  Adiponectin (ng/mL) 8969.2 (8008) 3333.2 (1788.8) 0.069
  Resistin (ng/mL) 14.9 (6.9) 14.1 (4.3) 0.76
  TnF-α (ng/mL) 1.6 (0.4) 1.6 (0.3) 0.86
  TnFR-1 (ng/mL) 1.2 (0.5) 1.2 (0.4) 0.99
  TnFR-2 (ng/mL) 2.6 (1.0) 3.0 (1.1) 0.41
Body composition
  Total body fat (kg) 15.6 (5.9) 28.2 (13.5) 0.007
  Total body lean (kg) 47.1 (3.7) 55.6 (9.9) 0.009
  Total body mass (kg) 64.8 (4.9) 86.4 (22.4) 0.008
Bone turnover markers
  Urinary nTX (nmol BCe/mmol creatinine) 38.4 (17.8) 27.9 (15.9) 0.18
  Osteocalcin (ng/mL) 5.3 (2.9) 3.8 (2.7) 0.28
hormones
  Testosterone (ng/dL) 340.2 (150.6)  319.9 (145.9) 0.75
  estradiol (pg/mL) 24.7 (12) 33.6 (19.0) 0.23
  25-OhD (ng/mL) 28.8 (15.7) 23.9 (9.1) 0.42
Lung function
  FeV1 % P 24.5 (7.9) 37 (10) 0.003
  TgV % P 210.3 (45.1) 173.2 (41.5) 0.08
  RV % P 258.5 (80) 194.2 (68.7) 0.08
  TLC % P 131.5 (21.8) 112.5 (21.8) 0.07
  DLCO % P 29.4 (10.2) 42.1 (16.2) 0.036
Notes:   Values given as mean (sD). aBased on dual-energy X-ray absorptiometry T-score or a history of osteoporotic fracture; bBased on dual-energy X-ray absorptiometry 
T-score.
Abbreviations:   TnF, tumor necrosis factor;   TnFR, tumor necrosis factor receptor; nTX, n-telopeptide; 25-OhD, 25-hydroxy vitamin D; FeV1 % P, forced expiratory volume 
in one second percent predicted; DLCO % P, diffusion capacity of carbon monoxide percent predicted;   TgV % P, thoracic gas volume percent predicted;   TLC % P, total lung 
capacity percent predicted; RV % P, residual volume percent predicted.International Journal of COPD 2009:4 275
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There are several limitations to this study. The sample 
size was small limiting the power to properly control for con-
founding variables and determine true associations. Venous 
blood samples were not collected in a fasting state or at the 
exact same time of the day in each patient, which may have 
impacted the adipokine levels. While it is standard to collect 
such samples after an overnight fast, there are several studies 
that indicate leptin and adiponectin levels do not substantially 
change postprandially.75–80 Therefore, we believe that the tim-
ing of the samples do not significantly impact our results. In 
addition, our results were consistent with what was expected 
based on the literature. Pulmonary function testing was not 
prospectively performed as a part of this study. Results 
were obtained from the patient’s medical record. While all 
pulmonary function tests results were performed at the UCH 
and during stable disease, some were obtained up to a year 
prior to enrollment into the study.
Our study demonstrated a high incidence of osteoporosis 
in men with severe COPD. Men with COPD and osteoporosis 
tended to have worse lung disease and significantly lower 
body mass and serum leptin concentrations compared to men 
with COPD, but without osteoporosis. Consistent with other 
studies, body weight was the only independent predictor of 
BMD in this population. This pilot study is important because 
it is the first study to evaluate the relationship between 
adipokines and BMD in patients with COPD. While these 
study results cannot refute or support the role of adipokines 
in the development of osteoporosis in men with COPD, 
it does bring into question whether the effect of body mass 
on BMD is mediated through the actions of adipokines on 
bone metabolism. Larger studies evaluating the potential role 
of adipokines in the development of osteoporosis are needed 
as well as research to better understand how low body weight 
contributes to low bone density in this population.
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